NEJM Trial on Mucoactive Therapies in Bronchiectasis: Structural Reassessment of Clinical Value
Click here to hear in youtube: https://youtu.be/jK6biROKjko
Source: NEJM (NEJMoa2510095, 2025), CLEAR Trial
Executive Summary
The CLEAR trial, published in the New England Journal of Medicine (2025), tested whether 6% hypertonic saline inhalation or oral carbocisteine reduced pulmonary exacerbations in adults with non–cystic fibrosis bronchiectasis. Conducted across 20 UK centers, 288 patients were randomized in a 2×2 factorial design and followed for 52 weeks.
Findings: Neither hypertonic saline nor carbocisteine significantly reduced exacerbation frequency versus standard care. The adjusted differences (–0.25 for saline, –0.04 for carbocisteine) were not statistically significant. Secondary outcomes—including quality of life, lung function, and time to next exacerbation—showed no consistent benefit.
Implication: Current guideline recommendations for universal use of these mucoactive agents in non-CF bronchiectasis are structurally weakened. Their role should shift toward selective, symptomatic use rather than systemic prescription.
Five Laws of Epistemic Integrity
1. Truthfulness of Information
Data drawn directly from a peer-reviewed NEJM trial.
Exacerbation counts, confidence intervals, and p-values transparently reported.
No evidence of data manipulation.
Verdict: High integrity.
2. Source Referencing
Primary: NEJM (NEJMoa2510095).
Secondary: PubMed indexing, trial registry references.
Independent commentary (TriBE MD, clinical society responses).
Verdict: High integrity.
3. Reliability & Accuracy
RCT, multicenter, open-label but rigorously adjudicated exacerbations.
Factorial design increases robustness.
Limitations: exclusion of smokers and recent mucoactive users reduces generalizability.
Verdict: Moderate–High integrity.
4. Contextual Judgment
Historical: mucoactives widely used with weak prior evidence base.
CLEAR trial marks the most definitive test to date.
Trend toward modest benefit of hypertonic saline (–0.25 exacerbations) may interest subgroups, but not strong enough for broad policy.
Verdict: Moderate integrity.
5. Inference Traceability
Clear line: Trial → No significant effect → Need for guideline revision.
Transparent inference: clinical adoption should be restricted to individualized symptomatic relief.
Verdict: High integrity.
BBIU Editorial
From Optamox to CLEAR: How N-Acetylcysteine Became the Illusion We All Paid For
For decades, doctors prescribed N-acetylcysteine (NAC) as if it were a hidden shield for the lungs. It was marketed as the substance that could “thin” mucus, make antibiotics work better, and prevent the spiral of infections that devastates people with chronic lung disease. The story was simple, elegant, and—above all—profitable.
In Argentina, one of the most striking examples was Optamox®, a combination pill of amoxicillin plus NAC. Advertised as “dual action,” it promised not only to kill bacteria but also to make airways cleaner and antibiotics more effective. It sounded rational. It looked innovative. It was also a myth sustained by marketing rather than by science.
No robust clinical trials ever showed that adding NAC to antibiotics improved outcomes. Yet patients and health systems paid more for this combination, believing they were buying something superior. In reality, they were financing an illusion: the packaging of an old antibiotic with a mucolytic that, at best, made patients feel like their sputum was looser, but did not change the course of their disease.
Now, in 2025, the illusion has collapsed. The CLEAR trial, published in the New England Journal of Medicine, is the largest and most rigorous study ever conducted on NAC in bronchiectasis (a chronic lung condition where airways are permanently widened and prone to infection). The verdict was blunt:
NAC did not reduce exacerbations.
NAC did not improve quality of life.
NAC did not change lung function or the need for antibiotics.
What it did increase were gastrointestinal side effects—and healthcare costs.
This is not just the fall of a single drug. It is the fall of a therapeutic narrative that persisted for decades without being questioned seriously. It shows how easy it is for a molecule to become part of “standard care” not because it works, but because it is marketed well and doctors repeat what they inherit.
The lesson is sobering:
For physicians, to demand evidence before habit.
For regulators, to protect patients from symbolic products that add cost without adding value.
For patients, to know that not everything sold as “dual action” or “enhanced” is truly better.
At BBIU we call this a structural correction. NAC has been demoted from “prophylactic therapy” to, at most, a symptomatic aid for those who personally feel relief when using it. It should never again be marketed as a protective strategy against exacerbations.
The case of Optamox now reads like a warning from the past: health systems spent millions on something that never delivered. The CLEAR trial finally puts the evidence on the table. The illusion is over.
Annex 1 – Technical Evidence Base
Bronchiectasis, Mucoactive Therapies, and Structural Context for Hydration and Airway Clearance
1. Definition of Bronchiectasis
Bronchiectasis is best understood not as a single disease but as the irreversible end result of diverse injuries to the airway. The bronchial walls, once thickened and destroyed, lose their elasticity and remain permanently dilated. No pharmacological intervention has ever been able to restore their architecture. For this reason, the therapeutic strategy is not curative but supportive: each intervention is a grain of sand that contributes to controlling symptoms, reducing infections, and maintaining an acceptable quality of life.
2. Etiology and Causes
The origins of bronchiectasis are varied and often complex. Some patients develop the condition after severe infections in childhood, such as tuberculosis or pneumonia, that leave structural scars. Others carry genetic defects, the most well-known being cystic fibrosis and primary ciliary dyskinesia, where abnormal secretions or immobile cilia impair airway clearance from birth. Immunodeficiency syndromes and autoimmune disorders can also undermine airway integrity, while allergic bronchopulmonary aspergillosis generates inflammation that gradually dilates the bronchi. In some cases, a tumor or a foreign body produces localized obstruction that evolves into permanent dilation. Yet in almost 40% of cases, even after exhaustive testing, no cause is identified, and the disease is labeled idiopathic. Whatever the trigger, the endpoint is the same: damaged bronchi that cannot drain mucus effectively.
3. Symptoms and Clinical Presentation
Patients with bronchiectasis typically live with daily cough and copious sputum, sometimes so abundant that entire cups are expectorated in the morning. Exacerbations punctuate their lives, episodes of acute deterioration that demand antibiotics and often hospital care. Dyspnea worsens over the years, hemoptysis alarms both patient and physician, and fatigue becomes constant. The disorder undermines appetite and weight, and in children, it stunts growth. The disease therefore is not just pulmonary; it becomes systemic, eroding the patient’s physical and psychological reserves.
4. Diagnostic Work-Up
The high-resolution CT scan is the defining tool, making visible the telltale “signet ring sign,” where a bronchus exceeds the size of its companion artery, tapering lost. Crackles, wheezing, and coarse sounds at auscultation are suggestive but not diagnostic. Pulmonary function tests reveal obstructive or mixed patterns but only describe functional loss. Microbiological cultures expose colonizing organisms, and further specialized tests — sweat chloride for cystic fibrosis, immunoglobulins for immunodeficiency, IgE for aspergillosis, or nasal nitric oxide for ciliary dyskinesia — search for underlying causes. The picture that emerges is always one of irreversible damage, confirmed radiologically and supported by microbiological evidence.
5. Pathogen Profile – Role of Pseudomonas aeruginosa
Among all microorganisms, Pseudomonas aeruginosa has a unique role in bronchiectasis. This Gram-negative bacillus, green with its characteristic pigments, thrives in damaged bronchi by forming biofilms that protect it against antibiotics and host defenses. Once it colonizes, it almost never leaves. Patients with Pseudomonas experience more exacerbations, more hospitalizations, and faster decline in lung function. Its presence signals a shift to a more severe disease phenotype and a significant rise in healthcare costs, as inhaled antibiotics and prolonged therapies become necessary.
6. Standard Care (Usual Care)
In modern health systems, “standard care” includes the sum of non-experimental practices: antibiotics to treat exacerbations, physiotherapy to aid secretion clearance, vaccination to prevent new infections, smoking cessation, and the management of comorbid conditions. Importantly, adequate hydration is assumed as part of baseline care. Yet here lies a silent structural flaw. Physicians instruct patients to “drink more water.” Patients, however, equate water with any liquid — coffee, tea, soda, mate, juice — many of which are diuretic or sugar-loaded and fail to hydrate the mucosa. Thus, what is officially considered standard care is often poorly executed in real life.
7. Hydration – Systemic vs Local
Hydration has two faces in bronchiectasis. Systemic hydration, achieved through pure water intake, maintains the periciliary fluid layer that allows mucus transport. Without it, mucus thickens and stagnates. Local hydration, through hypertonic saline nebulization, works directly at the airway surface: the 6% saline draws water into the lumen, thinning secretions and stimulating cough. CLEAR, the largest trial to date, tested this approach. The results showed only a modest, statistically non-significant reduction in exacerbations. The implication is clear: hydration helps with comfort and clearance, but cannot, on its own, alter the structural cycle of infection and inflammation.
8. Non-Pharmacological Clearance Strategies
Beyond hydration, airway clearance physiotherapy remains the cornerstone of care. Cochrane reviews confirm that techniques such as oscillatory positive expiratory pressure devices, postural drainage, or manual chest physiotherapy improve sputum clearance and patient-reported outcomes. Exercise and pulmonary rehabilitation enhance functional capacity and reduce dyspnea, although their impact on exacerbations is less robust. Together, these strategies represent the most cost-effective tools available. They demand time and commitment, but their efficacy exceeds that of pharmacological agents like NAC or even hypertonic saline when measured against real-world outcomes.
9. Health Economics
The economic burden of bronchiectasis is significant. Annual per-patient costs in Europe and the U.S. range from $7,000 to $15,000, rising above $25,000 when Pseudomonas colonization occurs. Hospitalizations are the main driver, costing $5,000–10,000 per admission, with one in four patients admitted at least once per year. Scaling to populations, a country with one million adults may see 1,000 hospitalizations annually, representing millions in direct expenditure. Interventions that reduce admissions by even 20–30%, such as structured physiotherapy or pulmonary rehabilitation, translate into substantial national savings. Hypertonic saline, however, fails to meet cost-effectiveness thresholds: the savings it provides are smaller than the costs of sustained implementation.
10. Structural Miscommunication in Hydration
The simplest intervention — adequate water intake — is undermined by communication failures. Telling a patient to “drink more water” is semantically insufficient. Cultural and marketing biases lead them to substitute coffee, tea, sodas, or flavored drinks, which physiologically do not hydrate. This transforms a virtually free, highly effective measure into a wasted opportunity. What is needed is explicit language: “When I say water, I mean pure water, without caffeine, carbonation, or sugar. At least 1.5 to 2 liters per day, separate from all other beverages.” Only such precision ensures that systemic hydration becomes real clinical practice rather than a misunderstood recommendation.
11. Structural Lessons and Final Synthesis
The lesson of bronchiectasis is sobering. Once the airways are dilated, they cannot be reversed. The best we can do is add interventions cumulatively, each contributing to life quality but never to anatomical cure. The CLEAR trial confirms that NAC is obsolete and that hypertonic saline offers, at best, modest symptomatic relief. Meanwhile, the truly effective strategies — physiotherapy, rehabilitation, education, and precise hydration — remain underutilized. The economic and clinical consequences of this misalignment are vast. Correcting miscommunication, institutionalizing physiotherapy, and abandoning ineffective pharmacological marketing represent the real path forward. In the end, the structural truth is simple: we cannot close the bronchi, but through incremental, well-targeted measures, we can still open life within them.
